Empagliflozin Reduces Ventricular Arrhythmias in Type 2 Diabetes Patients
Study Overview
Sodium-glucose cotransporter 2 (SGLT2) inhibitors like empagliflozin have shown benefits in reducing heart failure and cardiovascular death in type 2 diabetes patients. This study aimed to investigate the effects of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes who were treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator (ICD/CRT-D).
Results
Patients treated with empagliflozin showed a decrease in the number of ventricular arrhythmias recorded by ICD/CRT-D during treatment compared to before treatment, while the placebo group showed an increase. The change in the number of appropriate device discharges did not significantly differ between the groups. Additionally, empagliflozin was associated with changes in blood ketones, hematocrit, blood brain natriuretic peptide, and body weight.
Conclusion
In patients with type 2 diabetes treated with ICD/CRT-D, empagliflozin reduces the number of ventricular arrhythmias compared with placebo.
Practical Solutions: Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians. In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Value: By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines. Learn more about how we can help at aidevmd.com.
